English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Multiple myeloma (MM) cells interact with bone marrow stromal cells   stimulating transcription and secretion of cytokines like IL-6 and IL-10,   which are implicated in the progression and dissemination of MM. Regulation   of cytokines secretion is under genetic control through genetic polymorphisms   in their coding and promoter sequences. It seems that single nucleotide   polymorphism (SNP) in the promoter region of various genes may regulate the   plasma concentrations of cytokines. Cytokines could be also hypothesized to   function as pain modulators as peripheral nociceptors are sensitized by   cytokines. The aim was to determine if the SNP of IL-6 and IL-10 cytokines   could influence the analgesic response of radiotherapy in the treatment of   painful bone destructions in MM patients. 30 patients (19 women and 11 men,   median age: 67 years) with MM and painful bone destructions were treated with   palliative radiotherapy. Pain was evaluated according to the visual analogue   scale and analgesics intake. Pain scores and analgesics use were measured   prior to radiotherapy as well as 4, 12 and 24 weeks afterward. Opioid   analgesics were converted to the morphine-equivalent daily dose (MEDD).   Genomic DNA was extracted from peripheral blood leukocytes and IL-6 and IL-10   gene promoter polymorphisms were analysed with polymerase chain reaction. 60%   of patients reported severe pain prior to radiotherapy, which decreased to   13% at the first follow-up visit (p <0.001). The MEDD on admission to the   hospital was 75 mg/day which decreased to 46 mg/day at the first follow-up   visit (p = 0.033). A significant parameter in pain relief was: age < 65 years   (p=0.029). We analysed 6 SNPs in the gene promoter region of IL-6 (-597 G/A,   -572 G/C, -174 G/C) and IL-10 (-592 A/C, -819 C/T, -1082 A/G) as well as   their relation with pain severity and analgesic consumption. Patients who are   IL-10 -1082 A/G carriers are prone to respond better to radiotherapy than   other patients (p<0.05). A borderline association was noted for patients who   are IL-6 -597 A/A and G/G carriers - assumed to be at higher risk for severe   pain prior to radiotherapy (p=0.07) while for patients who are IL-10 - 1082   A/A carries: the median pain score decreased faster (p=0.08). Patients with   genotypes IL-6 -597 A/A and IL-6 -174 C/C required a smaller dose of opioids   (p=0.06). SNP of IL-6 and IL-10 cytokines can influence the analgesic   response of radiotherapy. Patients with genotype IL-10 -1082 A/G respond   better to radiotherapy

genetika

The role of single nucleotide polymorphism of IL-6 and IL-10 cytokine on pain severity and pain relief after radiotherapy in multiple myeloma patients with painful bone destructions